利妥昔单抗治疗难治性原发免疫性血小板减少症的研究进展

Research progress of Rituximab in the treatment of refractory primary immunologic thrombocytopenic purpura

原发免疫性血小板减少症(ITP)是一种免疫介导的获得性血小板减少所致的出血性疾病,对于进行诊断再评估仍确诊为ITP、脾切除无效或术后复发的ITP称为难治性ITP。由于发病机制复杂,目前临床上难治性ITP尚无统一的治疗方案。利妥昔单通过杀伤功能异常的B淋巴细胞,缓解血小板破坏从而对ITP起到良好的治疗作用。文章从利妥昔单抗治疗难治性ITP的作用机制、临床方案及疗效研究等方面进行综述,以期促进利妥昔单抗在难治性ITP治疗中的进一步研究。

Primary immunologic thrombocytopenic purpura(ITP)is a hemorrhagic disease caused by immune-mediated acquired thrombocytopenia,and it is called refractory ITP if ITP is still confirmed as ITP after diagnosis and reassessment,ineffective ITP with splenectomy or postoperative recurrence.Due to the complicated pathogenesis,there is currently no unified treatment plan for clinically refractory ITP.Rituximab has a good therapeutic effect on ITP by killing abnormal B lymphocytes and alleviating platelet destruction.This article reviews the mechanism of action,clinical program,and efficacy of Rituximab in the treatment of refractory ITP,with a view to promoting further research of Rituximab in the treatment of refractory ITP.